324 related articles for article (PubMed ID: 10522044)
21. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
22. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
Adsay NV; Basturk O; Cheng JD; Andea AA
Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
[TBL] [Abstract][Full Text] [Related]
23. Detection of K-ras point mutation at codon 12 in pancreatic diseases: a study in a Brazilian casuistic.
Kubrusly MS; Cunha JE; Bacchella T; Abdo EE; Jukemura J; Penteado S; Morioka CY; de Souza LJ; Machado MC
JOP; 2002 Sep; 3(5):144-51. PubMed ID: 12221329
[TBL] [Abstract][Full Text] [Related]
24. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma.
DiGiuseppe JA; Hruban RH; Offerhaus GJ; Clement MJ; van den Berg FM; Cameron JL; van Mansfeld AD
Am J Pathol; 1994 May; 144(5):889-95. PubMed ID: 8178941
[TBL] [Abstract][Full Text] [Related]
25. Detection of Ki-ras mutations by PCR and differential hybridization and of p53 mutations by SSCP analysis in endoscopically obtained lavage solution from patients with long-standing ulcerative colitis.
Lang SM; Heinzlmann M; Stratakis DF; Teschauer W; Loeschke K
Am J Gastroenterol; 1997 Dec; 92(12):2166-70. PubMed ID: 9399746
[TBL] [Abstract][Full Text] [Related]
26. p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy.
Kawahira H; Kobayashi S; Kaneko K; Asano T; Ochiai T
Hepatogastroenterology; 2000; 47(34):973-7. PubMed ID: 11020860
[TBL] [Abstract][Full Text] [Related]
27. Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor.
Hrasćan R; Pavelić K; Pavicić D; Krizanac S; Stajcer-Sittić V; Pecur L; Spaventi S; Klimpfinger M; Pavelić J
Anticancer Res; 1996; 16(6B):3761-6. PubMed ID: 9042254
[TBL] [Abstract][Full Text] [Related]
28. p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas.
Wada K
J Hepatobiliary Pancreat Surg; 2002; 9(1):76-85. PubMed ID: 12021900
[TBL] [Abstract][Full Text] [Related]
29. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region.
Sturm PD; Hruban RH; Ramsoekh TB; Noorduyn LA; Tytgat GN; Gouma DJ; Offerhaus GJ
J Pathol; 1998 Nov; 186(3):247-53. PubMed ID: 10211112
[TBL] [Abstract][Full Text] [Related]
30. [Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma].
Tomaszewska R
Folia Med Cracov; 1999; 40(1-2):101-41. PubMed ID: 10909469
[TBL] [Abstract][Full Text] [Related]
31. [Molecular diagnosis of pancreatic cancer].
Sugano K
Nihon Geka Gakkai Zasshi; 1997 Jul; 98(7):597-603. PubMed ID: 9276865
[TBL] [Abstract][Full Text] [Related]
32. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation.
Yamaguchi Y; Watanabe H; Yrdiran S; Ohtsubo K; Motoo Y; Okai T; Sawabu N
Clin Cancer Res; 1999 May; 5(5):1147-53. PubMed ID: 10353750
[TBL] [Abstract][Full Text] [Related]
33. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
[TBL] [Abstract][Full Text] [Related]
34. Characterization of K-ras gene mutations in association with mucinous hypersecretion in intraductal papillary-mucinous neoplasms.
Kobayashi N; Inamori M; Fujita K; Fujisawa T; Fujisawa N; Takahashi H; Yoneda M; Abe Y; Kawamura H; Shimamura T; Kirikoshi H; Kubota K; Sakaguchi T; Saito S; Saubermann LJ; Nakajima A
J Hepatobiliary Pancreat Surg; 2008; 15(2):169-77. PubMed ID: 18392710
[TBL] [Abstract][Full Text] [Related]
35. Detection of K-ras gene mutation at codon 12 by pancreatic duct brushing for pancreatic cancer.
Liu F; Li ZS; Xu GM; Sun ZX; Zhou GX; Ren XX; Tu ZX; Gong YF
Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):313-7. PubMed ID: 14599992
[TBL] [Abstract][Full Text] [Related]
36. K-ras mutation in focal proliferative lesions of human pancreas.
Terhune PG; Phifer DM; Tosteson TD; Longnecker DS
Cancer Epidemiol Biomarkers Prev; 1998 Jun; 7(6):515-21. PubMed ID: 9641496
[TBL] [Abstract][Full Text] [Related]
37. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
38. Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowskal H; Strzelczyk J; Janiak A; Malecka-Panas E
Hepatogastroenterology; 2006; 53(70):608-12. PubMed ID: 16995472
[TBL] [Abstract][Full Text] [Related]
39. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma.
Motojima K; Urano T; Nagata Y; Shiku H; Tsunoda T; Kanematsu T
Am J Gastroenterol; 1991 Dec; 86(12):1784-8. PubMed ID: 1962623
[TBL] [Abstract][Full Text] [Related]
40. Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution.
Soliman AS; Lo AC; Banerjee M; El-Ghawalby N; Khaled HM; Bayoumi S; Seifeldin IA; Abdel-Aziz A; Abbruzzese JL; Greenson JK; Hamilton SR
Carcinogenesis; 2007 Aug; 28(8):1794-9. PubMed ID: 17575320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
